Tevogen sees launch year oncology business revenue $1B

Tevogen (TVGN) reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1B in revenue in its launch year and a cumulative five-year estimate of between $10B and $14B. The forecast reflects the company’s drug development model. “With our intellectual property secured, Tevogen continues to build its U.S.-based cell therapy manufacturing capabilities, and I look forward to updating our shareholders on our forecasts and internal assets valuation,” commented Ryan Saadi, founder and CEO of Tevogen.

Protect Your Portfolio Against Market Uncertainty

Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on TVGN:

Disclaimer & DisclosureReport an Issue

Tevogen Bio Signs Agreement with CD 8 Technology Tevogen says Databricks commissioned to accelerate PredicTcell development Tevogen announces Tevogen Generics following Trump’s tariff-related statements Tevogen Bio Holdings Delays Annual Report Filing Tevogen announces new patent filed for T cell vaccine